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INTRODUCTION
Uveal metastasis of systemic carcinoma to the eye is estimated to 
occur in 8% of cases, according to the results of autopsy evaluations 
where microscopic detection rate is reported(1). The rate of intraocular 
metastasis varies according to the primary tumor site and the degree 
of systemic control. A previous report suggests that the frequency of 
macroscopic metastases has decreased over 12 years from 4.7% to 
1% owing to improved cancer therapy(2).
Uveal metastases occur far more frequently in the choroid than in 
the iris, possibly due to the substantial blood supply to the posterior 
choroid by the posterior ciliary arteries(3).
Metastatic tumors to the iris are relatively uncommon; they may 
present as stromal nodules or ill-defined iris thickening, or they may 
be associated with atypical features such as pain, iridocyclitis, and 
hyphema(4,5). In 2014, Shields et al. reported their 40-year experience 
of 104 cases of iris metastases arising from systemic cancer, demons-
trating the breast, lung, and skin as the most common primary sites 
for such lesions(4). 
Many of these patients are never examined by an ophthalmologist 
because many have no visual complaints or have systemic advanced 
disease.
Here, we describe three patients with iris metastasis and with diffe-
rent presentations and discuss the diagnostic challenges and unusual 
findings associated with these cases.
CASE REPORTS
Case 1
A 61-year-old man presented with a 3-month history of blurred 
vision affecting the right eye and the presence of iris lesion. His past 
ocular history was unremarkable, while his past medical history in-
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RESUMO
A maioria das metástases oculares do câncer sistêmico são encontrados na coroide. 
As metástases para a íris são incomuns, podendo se manifestar como nódulo es tro mal, 
espessamento de íris de limites mal definidos ou como uma iridociclite ou hifema. 
Relatamos 3 pacientes com lesão de íris e história pregressa de câncer sistêmico. 
Enfatizamos a dificuldade no diagnóstico e raridade dessas lesões comparando 
com relatos anteriores.
Descritores: Neoplasias da íris/metástase neoplásica; Relatos de casos
cluded a renal adenocarcinoma treated by total nephrectomy 5 years 
previously. Follow-up with imaging and laboratory studies demons-
trated no evidence of recurrence or metastatic disease.
On admission, ocular examination revealed a best-corrected vi-
sion of 20/30 in the right eye and 20/20 in the left eye. Full extraocular 
motion was observed. The pupils were 3 mm in diameter and reacti-
ve to light. The right pupil had an area of irregularity inferiorly, and 
there were neovessels in the collarette (Figure 1 A). A 2+/4+ anterior 
chamber reaction with no keratic precipitates were also observed. 
Further, a 7 × 4 mm pinkish-yellow mass from 1 to 5 o’clock with 
intrinsic friable vessels was observed, in addition to a band of tissue 
from 7 to 9 o’clock in the anterior chamber. The intraocular pressure 
was 25 mmHg (right eye) and 12 mmHg (left eye), as determined by 
applanation tonometry. Fundoscopic examination was normal. Based 
on all these findings, a clinical diagnosis of an iris tumor was made. 
Ultrasound biomicroscopy (UBM) of the right eye revealed an irido-
ciliary mass with homogeneous reflectivity, featuring areas of internal 
hyporeflective spaces within the tumor with clear margins (Figure 1 B). 
UBM of the left eye was normal.
Hypotensive agents and topical prednisolone 1% three times 
daily were initiated. Magnetic resonance imaging (MRI) revealed a 
renal mass, in addition to liver, brain, and pulmonary masses. A cli-
nical diagnosis of iridociliary metastasis arising from a primary renal 
carcinoma was established. Treatment with oral anti-tyrosinase was 
initiated, leading to shrinkage of both the iris and the systemic lesions 
(Figures 1 C and 1 D). The patient remains alive at 18 months after 
the initial diagnosis.
Case 2
A 58-year-old female presented with pain and blurred vision in 
her left eye. She had breast cancer, which was treated 10 years earlier 
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with mastectomy, lymphadenectomy, and systemic chemotherapy. 
Ocular examination revealed a best corrected vision of 20/20 in the 
right eye and finger-counting only in the left eye. Full extraocular 
motion was observed. The left pupil was slowly responsive to light, 
with an area of irregularity at 2 o’clock and a 3 × 2-mm white pearl 
mass in the temporal upper quadrant associated with bulging of the 
iris superiorly (Figure 2 A). Intense anterior chamber inflammation 
with 3+/4+ cells and an inferior white hypopyon without keratic 
precipitates was observed. UBM of the left eye revealed an iris lesion 
with heterogeneous reflectivity (Figure 2 B). Systemic work-up for 
Figure 1. Case 1. A) Photography demonstrating a 7 × 4-mm pinkish-yellow mass from 1 to 5 o’clock with intrinsic 
friable vessels. A band of tissue was observed from 7 to 9 o’clock in the anterior chamber. B) Ultrasound biomicroscopy 
(UBM) image of an iridociliary mass with homogeneous reflectivity and areas of internal hyporeflective spaces within 
the tumor. C and D) Post-treatment images demonstrating shrinkage of the lesion.
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Figure 2. Case 2. A) Photograph of a white pearl mass in the temporal upper quadrant associated with bulging of the 
iris superiorly. Intense anterior chamber inflammation with 3+/4+ cells was observed with an inferior white hypopyon 
without keratic precipitates. B) UBM image of the lesion with heterogeneous reflectivity. C) Lesion after treatment. 
D) Histopathology.
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Figure 3. Case 3. A) Biomicroscopy image demonstrating a pink iris mass from 1 to 3 o’clock with intrinsic vessels. B and C) 
Ultrasound biomicroscopy (UBM) demonstrating a mass with homogeneous reflectivity and areas of internal hyporeflective 
spaces. D) UBM after treatment showing shrinkage of the lesion.
inflammatory and infectious uveitis was negative. Other systemic me -
tastases were also ruled out. Findings of histological examination 
of an iris biopsy were highly suggestive of metastatic carcinoma 
(Figure 2 C). Immunohistochemical analyses were positive for CEA 
and CK7, and negative for estrogen. The patient was treated with 
external beam radiotherapy, with full regression of the lesion obser-
ved (Figure 2 D). After 13 months follow-up, no evidence of disease 
was observed at the primary site or other sites of metastatic disease.
Case 3
A 25-year-old woman presented with an iris lesion affecting her 
right eye and a 3-month history of blurred vision. Her past ocular 
history was unremarkable. She had an adenocarcinoma 1 year 
pre viously, which was treated by a total parotidectomy and a man-
dibulo-mastoidectomy with extraction of her cervical lymph nodes; 
however, surgical margins were not clear. Adjuvant external beam 
radiotherapy was performed at the surgical site. No evidence of local 
recurrence was observed on follow-up. Ocular examination revea-
led a best corrected vision of 20/100 in the right eye and 20/20 in 
the left eye. Full extraocular motion was observed. The right pupil 
was irregular and slowly responsive to light, with no signs of uveal 
inflammation. A pink iris mass was observed from 1 to 3 o’clock with 
the presence of intrinsic vessels (Figure 3 A). UBM of the right eye re-
vealed an iridociliary mass with homogeneous reflectivity and areas 
of internal hyporeflective spaces within the tumor (Figure 3 B and 3 C). 
A clinical diagnosis of metastatic disease was made. Full work-up, 
including positron emission tomography (PET), findings were nega-
tive. Plaque brachytherapy was performed to treat the focal iris me-
tastasis, with consequent lesion improvement observed (Figure 3 D). 
However, the patient died 10 months later due to the progression of 
metastatic disease.
DISCUSSION
In a clinical survey(6) of 3,680 iris tumors, 21% were reported as 
cystic and 79% as solid. In the solid group, 68% were melanocytic and 
11% were non-melanocytic. Non-melanocytic iris tumors included a 
range of diagnoses, including choristomatous, vascular, fibrous, neu-
ral, myogenic, epithelial, xanthomatous, metastatic, lymphoid, leukemic, 
and non-neoplastic conditions masquerading as iris masses. Only 67 
(2%) tumors were metastatic.
In the largest published series of 107 eyes with metastatic tumors 
of the iris, Shields et al.(4) reported primary tumors were more likely 
to originate from the breast (33%), lung (27%), skin (12%), kidney 
(7%), esophagus (3%), and other regions. The kidney and parotid are 
considered very rare primary tumor sites. Shields et al.(4) found that 
the majority of iris metastases were inferior (35%) and superior (28%), 
whereas the majority of cases were nasal (28%) or temporal (28%) in 
a series reported Ferry and Font(2). All three of our patients reported 
blurred vision, with the presence of non-melanocytic iris lesions on 
the nasal side in cases 1 and 3 and in the upper temporal region in 
case 2. Shields et al.(4) reported pain and blurred vision as the most 
common complaints, as observed in cases 1 and 2. Pain was related to 
secondary glaucoma in case 1 and to inflammation in case 2. All cases 
had a history of previously treated malignancy, as did the majority 
of patients in previous studies(4,5). Melanoma is considered the main 
differential diagnosis of iris metastasis, but it is clinically challenging 
to diagnose due to a lack of specific pathognomonic features(7).
UBM has been used to study and monitor iris tumors in previous 
studies(8); however, no pathognomic features have demonstrated 
utility in distinguishing melanomas from other metastases. In a series 
of UBM studies(8) of iris melanomas, two distinct patterns of tumor 
vascularity were observed by histological analysis with UBM: small 
hyperechoic dots relating to small-caliber vessels in the iris stroma; 
and hypoechoic spaces relating to larger vascular spaces. Cases 1 
and 3 exhibited the latter pattern, which may have been attributable 
to intrinsic vessels visible on slit lamp examination. In case 2, UBM 
de monstrated irregular reflectivity, with no visible intrinsic tumoral 
vessels observed on biomicroscopy. 
The majority of iris tumors can be diagnosed using clinical his-
torical criteria without the need for cytological or pathologic biopsy. 
In the largest series of fine-needle biopsies for iris tumors, the most 
common indications were suspected iris melanomas or metastases(9). 
In these cases, cytological evaluation of fine-needle aspirates was 
extremely helpful in distinguishing melanoma from metastatic neo-
plasm(9). We decided to perform a biopsy of the iris lesion in case 2 
as the patient had been treated for breast cancer 10 years previously 
without relapse, and she presented with no other metastatic foci. Further, 
as she also presented with signs of severe inflammation, biopsy was 
able to rule out infection. In cases 1 and 3, biopsy was not necessary 
as case 1 had a further metastatic focus, and the patient in case 3 
was young and had a local aggressive parotid adenocarcinoma with 
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involvement of the regional lymph nodes in addition to an iris lesion. 
Adenocarcinoma of the parotid develops from the secretory element 
of the gland and is considered an aggressive lesion with potential for 
both local lymphatic and distant metastasis(10). The patient in case 3 
died shortly after treatment of the iris lesion as she developed distant 
metastatic disease a few months later.
Unfortunately, the median time interval between the detection 
of iris metastasis and death is reportedly 24 months(4). It should be 
noted that cases 1 and 2 remain alive after follow-up durations of 18 
and 13 months, respectively.
The treatment of uveal metastases, including iris metastases, is 
palliative. Patients with other systemic involvement should be treated 
with systemic chemotherapy, while external radiotherapy or brachy-
therapy are recommended for the treatment of focal metastases. 
REFERENCES
 1. Bloch RS, Gartner S. The incidence of ocular metastatic carcinoma. Arch Ophthalmol. 
1971;85(6):673-5.
 2. Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal 
metastases. Ophthalmology. 1997;104(8):1265-76. 
 3. Shields CL, Kaliki S, Crabtree GS, Peshatani A, Morton S, Anand RA, et al. Iris metastasis 
from systemic cancer in 104 patients: The 2014 Jerry A. shields Lecture. Cornea. 2015; 
34(1):42-8.
 4. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. a clinic-pathological study 
of 227 cases. Arch Ophthalmol. 1974;92(4):276-86.
 5. Shields CL, Kancherla S, Patel J, Vijayvargiva P, Suriano MM, Kolbus E, et al. Clinical 
Survey of 3680 iris tumor based on the age at presentation. Opththalmology. 2012; 
119(2):407-14.
 6. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. II a clinic-pathological 
study of 26 patients with carcinoma metastatic to the anterior segment of the eye. 
Arch Ophthalmol. 1975;93(7):472-82.
 7. Hood CT, Schoenfield LR, Torres V, Singh AD. Iris melanoma. Ophthalmology. 2011; 
118(1):221-2. 
 8. Giuliari GP, McGowan HD, Pavlin CJ, Heathcote JG, Simpson ER. Ultrasound biomicros-
copic imaging of iris melanoma: a clinicopathologic study. Am J Ophthalmol. 2011; 
151(4):579-85. 
 9. Shields CL, Manquez ME, Ehya H, Mashayekhi A, Danzig CJ, Shields JA. Fine-needle 
aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications. 
Ophthalmology. 2006;113(11):2080-6. 
 10. Ho K, Lin H, Ann DK, Chu PG, Yen Y. An overview of the rare parotid gland cancer. Head 
& Neck Oncol. 2011;3:40. 
XVII Simpósio Internacional da  
Sociedade Brasileira de Glaucoma
25 a 27 de maio de 2017
Hotel Windsor Oceânico
Rio de Janeiro - RJ
Informações: 
E-mail: sbglaucoma2017@activiaconferences.com
